Interplay between tumor-associated macrophages and T lymphocytes affect the pathogenesis of hepatocellular carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHANG Yahui ¹ , CAI Dong ² ,  GONG Jianping ²

1. Department of Surgical Inpatient, Traditional Chinese Medical Hospital of Rongchang, Rongchang, Chongqing 402460, P. R. China;
2. Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400010, P. R. China;

Corresponding author：

GONG Jianping, Email: gongjianping11@126.com

Keywords：

hepatocellular carcinoma; tumor-associated macrophages; T lymphocyte; review

DOI：

10.7507/1007-9424.202002057

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To understand the interplay between tumor-associated macrophages (TAMs) and T lymphocytes, as well as the effect on the pathogenesis of hepatocellular carcinoma (HCC) again, so that providing new ideas and methods for the immunotherapy of HCC.Method Searched the literatures about the interplay between TAMs and T lymphocytes in HCC to analyze and summarize the relationship between TAMs and T lymphocytes in HCC.Results While TAMs and T lymphocytes themselves regulate the process of tumorigenesis and development, they also had a mutual regulatory mechanism to further promote the development of HCC.Conclusions There is an interaction between TAMs and T lymphocytes, and this interaction forms a vicious circle to a large extent and promotes the development of HCC. Recognizing and making rational use of this interaction can provide new ideas and methods for the future immunotherapy of HCC.

Citation： ZHANG Yahui, CAI Dong, GONG Jianping. Interplay between tumor-associated macrophages and T lymphocytes affect the pathogenesis of hepatocellular carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(10): 1325-1328. doi: 10.7507/1007-9424.202002057 Copy

1.	Bray F, Ferlay J, Soerjomataram I, <italic>et al</italic>. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	Yang JD, Hainaut P, Gores GJ, <italic>et al</italic>. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.
3.	Villanueva A. Hepatocellular carcinoma. N Engl J Med, 2019, 380(15): 1450-1462.
4.	Ringelhan M, Pfister D, O'Connor T, <italic>et al</italic>. The immunology of hepatocellular carcinoma. Nat Immunol, 2018, 19(3): 222-232.
5.	Chávez-Galán L, Olleros ML, Vesin D, <italic>et al</italic>. Much more than M1 and M2 macrophages, there are also CD169<sup>+</sup> and TCR<sup>+</sup> macrophages. Front Immunol, 2015, 6: 263.
6.	Degroote H, Van Dierendonck A, Geerts A, <italic>et al</italic>. Preclinical and clinical therapeutic strategies affecting tumor-associated macrophages in hepatocellular carcinoma. J Immunol Res, 2018, 2018: 7819520.
7.	Fu XT, Dai Z, Song K, <italic>et al</italic>. Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. Int J Oncol, 2015, 46(2): 587-596.
8.	Rai V, Abdo J, Alsuwaidan AN, <italic>et al</italic>. Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Mol Cell Biochem, 2018, 437(1-2): 13-36.
9.	Syn NL, Teng M, Mok T, <italic>et al</italic>. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol, 2017, 18(12): e731-e741.
10.	El-Khoueiry AB, Sangro B, Yau T, <italic>et al</italic>. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 2017, 389(10088): 2492-2502.
11.	Mossanen Jana C, Marlene K, Alexander W, <italic>et al</italic>. CXCR6 inhibits hepatocarcinogenesis by promoting natural killer T- and CD4<sup>+</sup> T-cell-dependent control of senescence. Gastroenterology, 2019, 156(6): 1877-1889. e4.
12.	Brown ZJ, Fu Q, Ma C, <italic>et al</italic>. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4<sup>+</sup> T cell apoptosis promoting HCC development. Cell Death Dis, 2018, 9(6): 620.
13.	Zhang H, Jiang Z, Zhang L. Dual effect of T helper cell 17(Th17) and regulatory T cell (Treg) in liver pathological process: From occurrence to end stage of disease. Int Immunopharmacol, 2019, 69: 50-59.
14.	Kang TW, Yevsa T, Woller N, <italic>et al</italic>. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature, 2011, 479(7374): 547-551.
15.	Eggert T, Wolter K, Ji J, <italic>et al</italic>. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer Cell, 2016, 30(4): 533-547.
16.	Hefetz-Sela S, Stein I, Klieger Y, <italic>et al</italic>. Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. Proc Natl Acad Sci U S A, 2014, 111(49): 17582-17587.
17.	Liu YT, Tseng TC, Soong RS, <italic>et al</italic>. A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment. J Immunother Cancer, 2018, 6(1): 144.
18.	Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol, 2015, 15(8): 486-499.
19.	Luca C, Takanori K. Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors. Front Cell Dev Biol, 2018, 6: 38.
20.	Ma J, Zheng B, Goswami S, <italic>et al</italic>. PD1Hi CD8<sup>+</sup> T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J Immunother Cancer, 2019, 7(1): 331.
21.	Liu J, Fan L, Yu H, <italic>et al</italic>. Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages. Hepatology, 2019, 70(1): 241-258.
22.	Li X, Yao W, Yuan Y, <italic>et al</italic>. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut, 2017, 66(1): 157-167.
23.	Yao W, Ba Q, Li X, <italic>et al</italic>. A natural CCR2 antagonist relieves tumor-associated macrophage-mediated immunosuppression to produce a therapeutic effect for liver cancer. EBioMedicine, 2017, 22: 58-67.
24.	Wu Q, Zhou W, Yin S, <italic>et al</italic>. Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed Cell death ligand 1 resistance in liver cancer. Hepatology, 2019, 70(1): 198-214.
25.	Li H, Wu K, Tao K, <italic>et al</italic>. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology, 2012, 56(4): 1342-1351.
26.	Wei Y, Lao XM, Xiao X, <italic>et al</italic>. Plasma cell polarization to the immunoglobulin G phenotype in hepatocellular carcinomas involves epigenetic alterations and promotes hepatoma progression in mice. Gastroenterology, 2019, 156(6): 1890-1904. e16.
27.	Wang C, Singer M, Anderson AC. Molecular dissection of CD8<sup>+</sup> T-cell dysfunction. Trends Immunol, 2017, 38(8): 567-576.
28.	Zou W, Wolchok JD, Chen L. PD-L1(B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med, 2016, 8(328): 328rv4.
29.	De Nardo DG, Barreto JB, Andreu P, <italic>et al</italic>. CD4<sup>+</sup> T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 2009, 16(2): 91-102.
30.	Ao JY, Zhu XD, Chai ZT, <italic>et al</italic>. Colony-stimulating factor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-associated macrophages in hepatocellular carcinoma. Mol Cancer Ther, 2017, 16(8): 1544-1554.

1. Bray F, Ferlay J, Soerjomataram I, <italic>et al</italic>. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. Yang JD, Hainaut P, Gores GJ, <italic>et al</italic>. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.
3. Villanueva A. Hepatocellular carcinoma. N Engl J Med, 2019, 380(15): 1450-1462.
4. Ringelhan M, Pfister D, O'Connor T, <italic>et al</italic>. The immunology of hepatocellular carcinoma. Nat Immunol, 2018, 19(3): 222-232.
5. Chávez-Galán L, Olleros ML, Vesin D, <italic>et al</italic>. Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages. Front Immunol, 2015, 6: 263.
6. Degroote H, Van Dierendonck A, Geerts A, <italic>et al</italic>. Preclinical and clinical therapeutic strategies affecting tumor-associated macrophages in hepatocellular carcinoma. J Immunol Res, 2018, 2018: 7819520.
7. Fu XT, Dai Z, Song K, <italic>et al</italic>. Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. Int J Oncol, 2015, 46(2): 587-596.
8. Rai V, Abdo J, Alsuwaidan AN, <italic>et al</italic>. Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Mol Cell Biochem, 2018, 437(1-2): 13-36.
9. Syn NL, Teng M, Mok T, <italic>et al</italic>. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol, 2017, 18(12): e731-e741.
10. El-Khoueiry AB, Sangro B, Yau T, <italic>et al</italic>. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 2017, 389(10088): 2492-2502.
11. Mossanen Jana C, Marlene K, Alexander W, <italic>et al</italic>. CXCR6 inhibits hepatocarcinogenesis by promoting natural killer T- and CD4+ T-cell-dependent control of senescence. Gastroenterology, 2019, 156(6): 1877-1889. e4.
12. Brown ZJ, Fu Q, Ma C, <italic>et al</italic>. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death Dis, 2018, 9(6): 620.
13. Zhang H, Jiang Z, Zhang L. Dual effect of T helper cell 17(Th17) and regulatory T cell (Treg) in liver pathological process: From occurrence to end stage of disease. Int Immunopharmacol, 2019, 69: 50-59.
14. Kang TW, Yevsa T, Woller N, <italic>et al</italic>. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature, 2011, 479(7374): 547-551.
15. Eggert T, Wolter K, Ji J, <italic>et al</italic>. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer Cell, 2016, 30(4): 533-547.
16. Hefetz-Sela S, Stein I, Klieger Y, <italic>et al</italic>. Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. Proc Natl Acad Sci U S A, 2014, 111(49): 17582-17587.
17. Liu YT, Tseng TC, Soong RS, <italic>et al</italic>. A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment. J Immunother Cancer, 2018, 6(1): 144.
18. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol, 2015, 15(8): 486-499.
19. Luca C, Takanori K. Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors. Front Cell Dev Biol, 2018, 6: 38.
20. Ma J, Zheng B, Goswami S, <italic>et al</italic>. PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J Immunother Cancer, 2019, 7(1): 331.
21. Liu J, Fan L, Yu H, <italic>et al</italic>. Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages. Hepatology, 2019, 70(1): 241-258.
22. Li X, Yao W, Yuan Y, <italic>et al</italic>. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut, 2017, 66(1): 157-167.
23. Yao W, Ba Q, Li X, <italic>et al</italic>. A natural CCR2 antagonist relieves tumor-associated macrophage-mediated immunosuppression to produce a therapeutic effect for liver cancer. EBioMedicine, 2017, 22: 58-67.
24. Wu Q, Zhou W, Yin S, <italic>et al</italic>. Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed Cell death ligand 1 resistance in liver cancer. Hepatology, 2019, 70(1): 198-214.
25. Li H, Wu K, Tao K, <italic>et al</italic>. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology, 2012, 56(4): 1342-1351.
26. Wei Y, Lao XM, Xiao X, <italic>et al</italic>. Plasma cell polarization to the immunoglobulin G phenotype in hepatocellular carcinomas involves epigenetic alterations and promotes hepatoma progression in mice. Gastroenterology, 2019, 156(6): 1890-1904. e16.
27. Wang C, Singer M, Anderson AC. Molecular dissection of CD8+ T-cell dysfunction. Trends Immunol, 2017, 38(8): 567-576.
28. Zou W, Wolchok JD, Chen L. PD-L1(B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med, 2016, 8(328): 328rv4.
29. De Nardo DG, Barreto JB, Andreu P, <italic>et al</italic>. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 2009, 16(2): 91-102.
30. Ao JY, Zhu XD, Chai ZT, <italic>et al</italic>. Colony-stimulating factor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-associated macrophages in hepatocellular carcinoma. Mol Cancer Ther, 2017, 16(8): 1544-1554.

Previous Article
The change of voice quality after thyroidectomy without recurrent laryngeal nerve injury

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Interplay between tumor-associated macrophages and T lymphocytes affect the pathogenesis of hepatocellular carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content